Skip to main content
[Preprint]. 2022 Apr 12:2022.04.11.487879. [Version 1] doi: 10.1101/2022.04.11.487879

Figure 5. COV44-62 and COV44-79 inhibit SARS-CoV-2 spike-mediated fusion and COV44-79 limits disease in a Syrian hamster model.

Figure 5.

(A) Images of fusion between HeLa cells stably expressing SARS-CoV-2 spike (RFP) and HeLa cells stably expressing the ACE2 receptor (GFP) after counter-staining with Hoechst (blue). Cells were co-cultured in the presence of COV44-62, COV44-79 or without a mAb (control). Scale bar, 500 μm.

(B) Weight change for SARS-CoV-2 naïve animals versus virus-exposed animals that were mock-treated or treated with 16 mg/kg of mAb. Statistical significance for average body weight was analyzed across the 7-day time-course using a mixed-effects repeated measures model with Dunnett’s post-test multiple comparison (n=12 animals from Day 0–6 and n=6 animals from Day 7–12). Error bars show mean ± SD.

(C and D) Clinical scores (C) and pathology scores (D) for SARS-CoV-2 naïve animals versus virus-exposed animals that were mock-treated or treated with 16 mg/kg of mAb. Statistical analyses for clinical (Days 0–7) and pathology (Days 3 and 7) scores were analyzed by a Kruskal-Wallis test with Dunn’s post-test multiple comparison (n=6–12 animals per condition), between the mAb-treated and mock-treated groups on each day. In (C), lines connect the median values. In (D), error bars show the median ± interquartile range.